Alnylam Pharmaceuticals (ALNY) Notes Payables (2024 - 2025)

Alnylam Pharmaceuticals (ALNY) posted Notes Payables of $121.3 million for Q3 2025, little changed on a QoQ basis from $120.8 million in Q2 2025.

Alnylam Pharmaceuticals (ALNY) Notes Payables (2024 - 2025) Analysis & Trends

Alnylam Pharmaceuticals' Notes Payables history runs 2 years deep, the most recent figure standing at $121.3 million for Q3 2025.

Quarterly Notes Payables changed N/A year-over-year to $121.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $121.3 million (changed N/A YoY) and the FY2024 annual result came in at $93.8 million, changed N/A from the prior year.
Notes Payables was $121.3 million for Q3 2025 at Alnylam Pharmaceuticals, roughly flat from $120.8 million in the prior quarter.
Across five years, Notes Payables topped out at $121.3 million in Q3 2025 and bottomed at $93.8 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Alnylam Pharmaceuticals	35.71 Bn	32.70 Bn	959.66 Mn

Download Data